Announcements
- Royalty Pharma to Present at TD Cowen’s 44th Annual Health Care Conference
- Royalty Pharma Reports Q4 and Full Year 2023 Results
- Royalty Pharma To Announce Fourth Quarter And Full Year 2023 Financial Results On February 15, 2024
- Royalty Pharma Announces Dividend Increase
- Royalty Pharma Highlights Accomplishments and Provides Business Update at 42nd Annual J.P. Morgan Healthcare Conference
- Royalty Pharma to Present at the Evercore ISI 6th Annual HealthCONx Conference
- Royalty Pharma and Teva Collaborate to Further Accelerate Olanzapine Lai Program
- Royalty Pharma Reports Third Quarter 2023 Results
- Royalty Pharma Announces Agreement to Purchase Up to $1.5 Billion of PTC Therapeutics’ Royalty on Evrysdi
- Royalty Pharma Declares Fourth Quarter 2023 Dividend
More ▼
Key statistics
On Thursday, Royalty Pharma PLC (RPD:FRA) closed at 27.92, 16.14% above the 52 week low of 24.04 set on Nov 30, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 27.84 |
---|---|
High | 27.92 |
Low | 27.84 |
Bid | -- |
Offer | -- |
Previous close | 27.75 |
Average volume | 339.70 |
---|---|
Shares outstanding | 597.43m |
Free float | 424.48m |
P/E (TTM) | 11.97 |
Market cap | 18.14bn USD |
EPS (TTM) | 2.54 USD |
Annual div (ADY) | 0.7797 EUR |
---|---|
Annual div yield (ADY) | 2.79% |
Div ex-date | Feb 15 2024 |
Div pay-date | Mar 15 2024 |
Data delayed at least 15 minutes, as of Mar 28 2024 14:03 BST.
More ▼